Financhill
Sell
38

CTMX Quote, Financials, Valuation and Earnings

Last price:
$1.09
Seasonality move :
-0.08%
Day range:
$1.03 - $1.10
52-week range:
$0.83 - $5.85
Dividend yield:
0%
P/E ratio:
6.41x
P/S ratio:
0.72x
P/B ratio:
--
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
-18.66%
Market cap:
$85.3M
Revenue:
$101.2M
EPS (TTM):
$0.17

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CTMX
CytomX Therapeutics
$17.1M -$0.18 -49.14% -153.35% --
IBIO
iBio
-- -$0.46 -100% -89.82% --
NBY
NovaBay Pharmaceuticals
$2.6M -$0.31 -60.77% -99.16% --
PTN
Palatin Technologies
-- -$0.51 -100% -25% --
SPRO
Spero Therapeutics
$7.7M -$0.36 -100% -505.55% $5.00
TOVX
Theriva Biologics
-- -$5.25 -- -8.25% $100.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CTMX
CytomX Therapeutics
$1.09 -- $85.3M 6.41x $0.00 0% 0.72x
IBIO
iBio
$2.48 -- $22.7M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.53 -- $2.6M -- $0.00 0% 0.06x
PTN
Palatin Technologies
$0.97 -- $18.9M -- $0.00 0% --
SPRO
Spero Therapeutics
$0.96 $5.00 $52.3M 12.00x $0.00 0% 0.58x
TOVX
Theriva Biologics
$1.14 $100.00 $3.2M -- $0.00 0% 0.90x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CTMX
CytomX Therapeutics
-- 4.423 -- 1.01x
IBIO
iBio
4.41% 6.097 5.41% 3.89x
NBY
NovaBay Pharmaceuticals
4.54% 0.704 1.51% 0.75x
PTN
Palatin Technologies
-- -0.872 -- 0.99x
SPRO
Spero Therapeutics
-- 2.060 -- 2.64x
TOVX
Theriva Biologics
-- -1.027 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CTMX
CytomX Therapeutics
-- $4.1M -- -- 12.3% -$20.7M
IBIO
iBio
-- -$4.1M -90.99% -148.3% -1820.57% -$3.7M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M
SPRO
Spero Therapeutics
-- -$18.6M 4.36% 4.36% -237.79% $12.8M
TOVX
Theriva Biologics
-- -$5M -- -- -- -$3.9M

CytomX Therapeutics vs. Competitors

  • Which has Higher Returns CTMX or IBIO?

    iBio has a net margin of 17.16% compared to CytomX Therapeutics's net margin of -4444.57%. CytomX Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTMX
    CytomX Therapeutics
    -- $0.07 -$23.5M
    IBIO
    iBio
    -- -$0.46 $22.3M
  • What do Analysts Say About CTMX or IBIO?

    CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that CytomX Therapeutics has higher upside potential than iBio, analysts believe CytomX Therapeutics is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTMX
    CytomX Therapeutics
    0 0 0
    IBIO
    iBio
    0 0 0
  • Is CTMX or IBIO More Risky?

    CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

  • Which is a Better Dividend Stock CTMX or IBIO?

    CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTMX or IBIO?

    CytomX Therapeutics quarterly revenues are $33.4M, which are larger than iBio quarterly revenues of $175K. CytomX Therapeutics's net income of $5.7M is higher than iBio's net income of -$4M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTMX
    CytomX Therapeutics
    0.72x 6.41x $33.4M $5.7M
    IBIO
    iBio
    -- -- $175K -$4M
  • Which has Higher Returns CTMX or NBY?

    NovaBay Pharmaceuticals has a net margin of 17.16% compared to CytomX Therapeutics's net margin of -49.65%. CytomX Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTMX
    CytomX Therapeutics
    -- $0.07 -$23.5M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About CTMX or NBY?

    CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than CytomX Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than CytomX Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTMX
    CytomX Therapeutics
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    0 0 0
  • Is CTMX or NBY More Risky?

    CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

  • Which is a Better Dividend Stock CTMX or NBY?

    CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTMX or NBY?

    CytomX Therapeutics quarterly revenues are $33.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CytomX Therapeutics's net income of $5.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTMX
    CytomX Therapeutics
    0.72x 6.41x $33.4M $5.7M
    NBY
    NovaBay Pharmaceuticals
    0.06x -- $2.4M -$1.2M
  • Which has Higher Returns CTMX or PTN?

    Palatin Technologies has a net margin of 17.16% compared to CytomX Therapeutics's net margin of -2357.27%. CytomX Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTMX
    CytomX Therapeutics
    -- $0.07 -$23.5M
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About CTMX or PTN?

    CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than CytomX Therapeutics, analysts believe Palatin Technologies is more attractive than CytomX Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTMX
    CytomX Therapeutics
    0 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is CTMX or PTN More Risky?

    CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

  • Which is a Better Dividend Stock CTMX or PTN?

    CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTMX or PTN?

    CytomX Therapeutics quarterly revenues are $33.4M, which are larger than Palatin Technologies quarterly revenues of $350K. CytomX Therapeutics's net income of $5.7M is higher than Palatin Technologies's net income of -$7.8M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTMX
    CytomX Therapeutics
    0.72x 6.41x $33.4M $5.7M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
  • Which has Higher Returns CTMX or SPRO?

    Spero Therapeutics has a net margin of 17.16% compared to CytomX Therapeutics's net margin of -219.3%. CytomX Therapeutics's return on equity of -- beat Spero Therapeutics's return on equity of 4.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTMX
    CytomX Therapeutics
    -- $0.07 -$23.5M
    SPRO
    Spero Therapeutics
    -- -$0.32 $65.5M
  • What do Analysts Say About CTMX or SPRO?

    CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 421%. Given that Spero Therapeutics has higher upside potential than CytomX Therapeutics, analysts believe Spero Therapeutics is more attractive than CytomX Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTMX
    CytomX Therapeutics
    0 0 0
    SPRO
    Spero Therapeutics
    1 2 0
  • Is CTMX or SPRO More Risky?

    CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.892%.

  • Which is a Better Dividend Stock CTMX or SPRO?

    CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTMX or SPRO?

    CytomX Therapeutics quarterly revenues are $33.4M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. CytomX Therapeutics's net income of $5.7M is higher than Spero Therapeutics's net income of -$17.1M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while Spero Therapeutics's PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus 0.58x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTMX
    CytomX Therapeutics
    0.72x 6.41x $33.4M $5.7M
    SPRO
    Spero Therapeutics
    0.58x 12.00x $7.8M -$17.1M
  • Which has Higher Returns CTMX or TOVX?

    Theriva Biologics has a net margin of 17.16% compared to CytomX Therapeutics's net margin of --. CytomX Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTMX
    CytomX Therapeutics
    -- $0.07 -$23.5M
    TOVX
    Theriva Biologics
    -- -$6.81 --
  • What do Analysts Say About CTMX or TOVX?

    CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 7838.6%. Given that Theriva Biologics has higher upside potential than CytomX Therapeutics, analysts believe Theriva Biologics is more attractive than CytomX Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTMX
    CytomX Therapeutics
    0 0 0
    TOVX
    Theriva Biologics
    1 0 0
  • Is CTMX or TOVX More Risky?

    CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

  • Which is a Better Dividend Stock CTMX or TOVX?

    CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTMX or TOVX?

    CytomX Therapeutics quarterly revenues are $33.4M, which are larger than Theriva Biologics quarterly revenues of --. CytomX Therapeutics's net income of $5.7M is higher than Theriva Biologics's net income of -$7.7M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTMX
    CytomX Therapeutics
    0.72x 6.41x $33.4M $5.7M
    TOVX
    Theriva Biologics
    0.90x -- -- -$7.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 6.3% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 9.68% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.97% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock